Special Issue

Bacterial Infections and Global Health: The Escalating Threat of Antibiotic Resistance

Message from the Guest Editors

Bacterial infections, particularly those caused by multidrug-resistant pathogens, are a critical global health concern. Antimicrobial resistance (AMR) is one of the top threats to public health and development, directly causing 1.27 million deaths in 2019 and contributing to 4.95 million more. By 2050, AMR-related mortality is projected to reach 4.73 million in Asia, 4.15 million in Africa, 0.39 million in Europe, 0.392 million in Latin America, 0.317 million in North America, and 0.022 million in Oceania. Developing countries are especially vulnerable due to the misuse and overuse of antimicrobials in humans, animals, and plants. This exacerbates challenges such as limited treatment options, prolonged hospital stays, higher costs, and increased morbidity and mortality. This Special Issue will prioritize topics addressing AMR in human health, including infection prevention, antimicrobial stewardship, AMR surveillance, access to quality diagnoses and treatments, and innovations in vaccines, diagnostics, and medicines.

Guest Editors

Prof. Dr. Nicola Petrosillo

Infection Prevention & Control and Infectious Disease Unit, University Hospital "Campus Bio-Medico", 00128 Rome, Italy

Dr. Guido Granata

Clinical and Research Department, National Institute for Infectious Diseases "L. Spallanzani" IRCCS, Rome, Italy

Deadline for manuscript submissions

31 January 2026



an Open Access Journal by MDPI

Impact Factor 4.6
CiteScore 8.7
Indexed in PubMed



mdpi.com/si/223400

Antibiotics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
antibiotics@mdpi.com

mdpi.com/journal/ antibiotics





an Open Access Journal by MDPI

Impact Factor 4.6 CiteScore 8.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery. use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. Antibiotics is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and Molecular Bioscience, University of Wollongong, Wollongong, NSW 2522, Australia

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Infectious Diseases) / CiteScore - Q1 (General Pharmacology, Toxicology and Pharmaceutics)

